CoChat

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

Open access
Danese, Silvio, Gomollon, Fernando, on behalf of the Governing Board and Operational Board of ECCO · 2013 · Journal of Crohn's and Colitis
Cited by 192

The DOI matches its Crossref record.

Abstract

Biologics have become key agents for the management of Crohn's disease and ulcerative colitis. Biosimilars are biological medicines similar to previously authorized biologics and are already available in some countries. This ECCO Position Statement defines the collective view of European specialist in inflammatory bowel disease (IBD) concerning biosimilars. Biosimilars are not comparable to generic small molecules, since both efficacy and toxicity are difficult to predict due to subtle molecular changes that can have profound effects on clinical efficacy and immunogenicity. Direct evidence of safety and benefit from clinical trials in IBD, post-marketing pharmacoviligance, and unequivocal identification of the product as a biosimilar should be requirements before approval. Switching from an established biologic to a biosimilar to save costs is likely to be as inappropriate and inefecctive as switching between current biologics that act on the same target, except when there is loss of response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.crohns.2013.03.011

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 192

Metadata

Authors
Danese, S., Gomollon, F., & on behalf of the Governing Board and Operational Board of ECCO
Venue
Journal of Crohn's and Colitis
Published
2013-08-01
Volume
7
Issue
7
Pages
586-589
ISSN
  • 1873-9946 (ISSN-L)
  • 1876-4479
OpenAlex
W2149858688
Cited by
192
References
0
FWCI
12.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). https://app.cochat.ai/papers/10.1016/j.crohns.2013.03.011
The paper
Danese, S., Gomollon, F., & on behalf of the Governing Board and Operational Board of ECCO. (2013). ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). Journal of Crohn's and Colitis. https://doi.org/10.1016/j.crohns.2013.03.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.